Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazine (PA-824)

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 282-294

  Palmer, Brian D ^a   Thompson, Andrew M ^a   Sutherland, Hamish S ^a   Blaser, Adrian ^a   Kmentova, Iveta ^a   Franzblau, Scott G ^b   Wan, Baojie ^b   Wang, Yuehong ^b   Ma, Zhenkun ^c   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849116658     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901207n     Document Type: Article

References (25)

1. World Health Organization (WHO) Tuberculosis fact sheet No. 104; revised March 2007.
2. Laurenzi, M.; Ginsberg, A.; Spigelman, M. Challenges associated with current and future TB treatment. Infect. Disord. - Drug Targets 2007, 7, 105-119.
3. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405, 962-966.
4. Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 2006, 49, 7854-7860.
5. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro- imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006, 3, 2131-2143.
6. Rivers, E. C.; Mancera, R. L. New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem. 2008, 15, 1956-1967.
7. Ma, Z.; Ginsberg, A. M.; Spigelman, M. Antimycobacterium agents. In Comprehensive Medicinal Chemistry II; Taylor, J. B.; Triggle, D. J., Eds.; Elsevier: Oxford, 2006; Vol. 7; pp 699-730.
8. Thompson, A. M.; Blaser, A.; Anderson, R. F.; Shinde, S. S.; Franzblau, S. G.; Ma, Z.; Denny, W. A.; Palmer, B. D. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J. Med. Chem. 2009, 52, 637-645.
9. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 431-436.
10. Guillemont, J.; Lieby-Muller, F.; Lounis, N.; Balemans, W.; Koul, A.; Andries, K. New anti-tuberculosis drugs in clinical development: an overview. Curr. Bioactive Compd. 2009, 5, 137-154.
11. Tam, C.-M.; Yew, W.-W.; Yuen, K.-Y. Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects. Exp. Rev. Clin. Pharmacol. 2009, 2, 405-421.
12. Tasneen, R.; Tyagi, S.; Williams, K.; Grosset, J.; Nuermberger, E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008, 52, 3664-3668.
13. (a) Baker W. R.; Shaopei, C.; Keeler, E. L. Nitroimidazole anti-bacterial compounds and methods of use thereof. U.S. Patent 5,668,127, 1997;
14. (b) Nitro-[2,1-b]imidazopyran compounds and anti-bacterial uses thereof. U.S. Patent 6,087,358, 2000.
15. Li, X.; Manjunatha, U. H.; Goodwin,M. B.; Knox, J. E.; Lipinski, C. A.; Keller, T. H.; Barry, C. E.; Dowd, C. S. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4- (trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo-[2,1-b][1,3] oxazines, analogues of PA-824. Bioorg. Med. Chem. Lett. 2008, 18, 2256-2262.
16. Kim, P.; Zhang, L.; Manjunatha, U. H.; Singh, R.; Patel, S.; Jiricek, J.; Keller, T. H.; Boshoff, H. I.; Barry, C. E.; Dowd, C. S. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J. Med. Chem. 2009, 52, 1317-1328.
17. Kim, P.; Kang, S.; Boshoff, H. I.; Jiricek, J.; Collins, M.; Singh, R.; Manjunatha, U. H.; Niyomrattanakit, P.; Zhang, L.; Goodwin, M.; Dick, T.; Keller, T. H.; Dowd, C. S.; Barry, C. E. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J. Med. Chem. 2009, 52, 1329-1344.
18. Anderson, R. F.; Shinde, S. S.; Maroz, A.; Boyd, M.; Palmer, B. D.; Denny,W. A. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Org. Biomol. Chem. 2008, 6, 1973-1980.
19. Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322, 1392-1395.
20. Ginsberg, A. M.; Laurenzi, M. W.; Rouse, D. J.; Whitney, K. D.; Spigelman, M. K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 2009, 53, 3720-3725.
21. O'Shea, P. D.; Chen, C.-Y.; Chen, W.; Dagneau, P.; Frey, L. F.; Grabowski, E. J. J.; Marcantonio, K. M.; Reamer, R. A.; Tan, L.; Tillyer, R. D.; Roy, A.; Wang, X.; Zhao, D. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate. J. Org. Chem. 2005, 70, 3021-3030.
22. Collins, L. A.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997, 41, 1004-1009.
23. Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2007, 51, 1380-1385.
24. Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2005, 49, 1447-1454.
25. Barry, C. E.; Crick, D. C.; McNeil, M. R. Targeting the formation of the cell wall core of M. tuberculosis. Infect. Disord. - Drug Targets 2007, 7, 182-202.